1.
Tha├ži D, Armstrong A, Lebwohl M, Blauvelt A, Paul C, Puig L, Wang M, Vanvoorden V, Madden C, Wiegratz S, Deherder D, Gordon K. Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials. J of Skin [Internet]. 2022Nov.16 [cited 2023Sep.21];6(6):s71. Available from: https://jofskin.org/index.php/skin/article/view/1827